305 related articles for article (PubMed ID: 32053670)
21. The predictive value of coexisting BRAFV600E and TERT promoter mutations on poor outcomes and high tumour aggressiveness in papillary thyroid carcinoma: A systematic review and meta-analysis.
Chen B; Shi Y; Xu Y; Zhang J
Clin Endocrinol (Oxf); 2021 May; 94(5):731-742. PubMed ID: 32816325
[TBL] [Abstract][Full Text] [Related]
22. Relation Between F-18 FDG Uptake of PET/CT and BRAFV600E Mutation in Papillary Thyroid Cancer.
Yoon S; An YS; Lee SJ; So EY; Kim JH; Chung YS; Yoon JK
Medicine (Baltimore); 2015 Dec; 94(48):e2063. PubMed ID: 26632889
[TBL] [Abstract][Full Text] [Related]
23. Preoperative detection of TERT promoter and BRAFV600E mutations in papillary thyroid carcinoma in high-risk thyroid nodules.
Giorgenon TMV; Carrijo FT; Arruda MA; Cerqueira TLO; Barreto HR; Cabral JB; Silva TMD; Magalhães PKR; Maciel LMZ; Ramos HE
Arch Endocrinol Metab; 2019; 63(2):107-112. PubMed ID: 30916166
[TBL] [Abstract][Full Text] [Related]
24. Association Between Radiomics Signature and Disease-Free Survival in Conventional Papillary Thyroid Carcinoma.
Park VY; Han K; Lee E; Kim EK; Moon HJ; Yoon JH; Kwak JY
Sci Rep; 2019 Mar; 9(1):4501. PubMed ID: 30872763
[TBL] [Abstract][Full Text] [Related]
25. Generation of a Potential Prognostic Matrix for Papillary Thyroid Cancer that Assesses Age, Tumor Size, Transforming Growth Factor-β, and BRAFV600E Mutation.
Wang P; Lun Y; Fu Y; Wang F; Zhao S; Wang Y; Hou X
Oncol Res Treat; 2017; 40(10):586-592. PubMed ID: 28892804
[TBL] [Abstract][Full Text] [Related]
26. Stomatin-like protein 2 overexpression in papillary thyroid carcinoma is significantly associated with high-risk clinicopathological parameters and BRAFV600E mutation.
Bartolome A; Boskovic S; Paunovic I; Bozic V; Cvejic D
APMIS; 2016 Apr; 124(4):271-7. PubMed ID: 26750533
[TBL] [Abstract][Full Text] [Related]
27. Ultrasound images-based deep learning radiomics nomogram for preoperative prediction of
Yu J; Zhang Y; Zheng J; Jia M; Lu X
Front Endocrinol (Lausanne); 2022; 13():1062571. PubMed ID: 36605945
[TBL] [Abstract][Full Text] [Related]
28. Association Between Obesity and BRAFV600E Mutation Status in Patients with Papillary Thyroid Cancer.
Lee J; Lee CR; Ku CR; Kang SW; Jeong JJ; Shin DY; Nam KH; Jung SG; Lee EJ; Chung WY; Jo YS
Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S683-90. PubMed ID: 26215201
[TBL] [Abstract][Full Text] [Related]
29. BRAFV600E and RET/PTC Promote Proliferation and Migration of Papillary Thyroid Carcinoma Cells In Vitro by Regulating Nuclear Factor-κB.
Zhou D; Li Z; Bai X
Med Sci Monit; 2017 Nov; 23():5321-5329. PubMed ID: 29117154
[TBL] [Abstract][Full Text] [Related]
30. Tumor genotype determines phenotype and disease-related outcomes in thyroid cancer: a study of 1510 patients.
Yip L; Nikiforova MN; Yoo JY; McCoy KL; Stang MT; Armstrong MJ; Nicholson KJ; Ohori NP; Coyne C; Hodak SP; Ferris RL; LeBeau SO; Nikiforov YE; Carty SE
Ann Surg; 2015 Sep; 262(3):519-25; discussion 524-5. PubMed ID: 26258321
[TBL] [Abstract][Full Text] [Related]
31. The synergic effect of BRAF
Qu HJ; Qu XY; Hu Z; Lin Y; Wang JR; Zheng CF; Tan Z
Endocr J; 2018 Jan; 65(1):113-120. PubMed ID: 29070763
[TBL] [Abstract][Full Text] [Related]
32. A different prognostic value of BRAFV600E mutation positivity in various age groups of patients with papillary thyroid cancer.
Takacsova E; Kralik R; Waczulikova I; Zavodna K; Kausitz J
Neoplasma; 2017; 64(1):156-164. PubMed ID: 27881018
[TBL] [Abstract][Full Text] [Related]
33. Radiomics based on multiparametric MRI for extrathyroidal extension feature prediction in papillary thyroid cancer.
Wei R; Wang H; Wang L; Hu W; Sun X; Dai Z; Zhu J; Li H; Ge Y; Song B
BMC Med Imaging; 2021 Feb; 21(1):20. PubMed ID: 33563233
[TBL] [Abstract][Full Text] [Related]
34. Distinctive Desmoplastic 3D Morphology Associated With BRAFV600E in Papillary Thyroid Cancers.
Tarabichi M; Antoniou A; Le Pennec S; Gacquer D; de Saint Aubain N; Craciun L; Cielen T; Laios I; Larsimont D; Andry G; Dumont JE; Maenhaut C; Detours V
J Clin Endocrinol Metab; 2018 Mar; 103(3):1102-1111. PubMed ID: 29342254
[TBL] [Abstract][Full Text] [Related]
35. Aberrant hypermethylation of the HOXD10 gene in papillary thyroid cancer with BRAFV600E mutation.
Cao YM; Gu J; Zhang YS; Wei WJ; Qu N; Wen D; Liao T; Shi RL; Zhang L; Ji QH; Wang Y; Sun GH; Zhao YX; Wang YJ; Yu J; Zhu YX
Oncol Rep; 2018 Jan; 39(1):338-348. PubMed ID: 29115628
[TBL] [Abstract][Full Text] [Related]
36. Clinicopathological Features and Prognosis of Papillary Thyroid Microcarcinoma for Surgery and Relationships with the BRAFV600E Mutational Status and Expression of Angiogenic Factors.
Shi C; Guo Y; Lv Y; Nanding A; Shi T; Qin H; He J
PLoS One; 2016; 11(12):e0167414. PubMed ID: 27936049
[TBL] [Abstract][Full Text] [Related]
37. Nomogram based on radiomics analysis of ultrasound images can improve preoperative
Tang J; Jiang S; Ma J; Xi X; Li H; Wang L; Zhang B
Front Endocrinol (Lausanne); 2022; 13():915135. PubMed ID: 36060960
[TBL] [Abstract][Full Text] [Related]
38. BRAFV600E status and clinical characteristics in solitary and multiple papillary thyroid carcinoma: experience of 512 cases at a clinical center in China.
Zheng X; Xia T; Lin L; Gao S; Lee Y; Yu Y; Wei S; Gao M
World J Surg Oncol; 2012 Jun; 10():104. PubMed ID: 22681706
[TBL] [Abstract][Full Text] [Related]
39. Association of Polygenic Score With Tumor Molecular Subtypes in Papillary Thyroid Carcinoma.
Wang JR; Zafereo ME; Wang W; Joshu C; Ray D
J Clin Endocrinol Metab; 2023 Dec; 109(1):e306-e313. PubMed ID: 37453101
[TBL] [Abstract][Full Text] [Related]
40. Clinical implications of the BRAF mutation in papillary thyroid carcinoma and chronic lymphocytic thyroiditis.
Kim WW; Ha TK; Bae SK
J Otolaryngol Head Neck Surg; 2018 Jan; 47(1):4. PubMed ID: 29316976
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
